Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Brivaracetam for the treatment of epilepsy in adults.

Mula M.

Expert Rev Neurother. 2014 Apr;14(4):361-5. doi: 10.1586/14737175.2014.896200. Review.

PMID:
24625006
2.

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.

Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8.

3.

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):38-46. doi: 10.1111/epi.12391. Epub 2013 Oct 3.

4.

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):47-56. doi: 10.1111/epi.12432. Epub 2013 Oct 28.

5.

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.

Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P.

Epilepsia. 2013 Jan;54(1):89-97. doi: 10.1111/j.1528-1167.2012.03598.x. Epub 2012 Jul 19.

6.

Brivaracetam for the treatment of epilepsy.

Schulze-Bonhage A.

Expert Opin Pharmacother. 2011 Aug;12(12):1959-66. doi: 10.1517/14656566.2011.591380. Epub 2011 Jun 20. Review.

PMID:
21682662
7.

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.

Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P.

Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212. Epub 2015 Oct 16.

PMID:
26471380
8.

Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials.

Ma J, Huang S, You C.

Epilepsy Res. 2015 Aug;114:59-65. doi: 10.1016/j.eplepsyres.2015.04.017. Epub 2015 May 1. Review.

PMID:
26088886
9.

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H.

Br J Pharmacol. 2008 Aug;154(8):1662-71. doi: 10.1038/bjp.2008.198. Epub 2008 May 26.

10.

Pharmacotherapy of epilepsy: newly approved and developmental agents.

Stephen LJ, Brodie MJ.

CNS Drugs. 2011 Feb;25(2):89-107. doi: 10.2165/11584860-000000000-00000. Review.

PMID:
21254787
11.

The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.

Tian X, Yuan M, Zhou Q, Wang X.

Expert Opin Pharmacother. 2015;16(12):1755-67. doi: 10.1517/14656566.2015.1058360. Epub 2015 Jul 13.

PMID:
26165169
12.

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

French JA, Costantini C, Brodsky A, von Rosenstiel P; N01193 Study Group.

Neurology. 2010 Aug 10;75(6):519-25. doi: 10.1212/WNL.0b013e3181ec7f7f. Epub 2010 Jun 30.

PMID:
20592253
13.

Brivaracetam (UCB 34714).

von Rosenstiel P.

Neurotherapeutics. 2007 Jan;4(1):84-7. Review.

PMID:
17199019
14.

Emerging drugs for partial-onset epilepsy: a review of brivaracetam.

Gao L, Li S.

Ther Clin Risk Manag. 2016 May 4;12:719-34. doi: 10.2147/TCRM.S90127. eCollection 2016.

15.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.

Epilepsia. 2016 Apr;57(4):538-48. doi: 10.1111/epi.13340. Epub 2016 Feb 26. Review.

PMID:
26920914
16.

Brivaracetam: a new drug in development for epilepsy and neuropathic pain.

Malawska B, Kulig K.

Expert Opin Investig Drugs. 2008 Mar;17(3):361-9. doi: 10.1517/13543784.17.3.361 . Review.

PMID:
18321235
17.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

18.

Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.

Brochot A, Zamacona M, Stockis A.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):256-62. doi: 10.1111/j.1742-7843.2009.00536.x. Epub 2010 Jan 25. Review.

19.

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T.

Epilepsia. 2006 Jul;47(7):1094-120. Review.

20.

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.

Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E, Gambardella A, De Sarro G, Russo E.

Drug Des Devel Ther. 2015 Oct 19;9:5719-25. doi: 10.2147/DDDT.S81474. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:6509.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk